Corticosteroid therapy does not alter the threshold for contraction-induced injury in dystrophic (MDX) mouse diaphragm
Liying Yang MD
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Respiratory Muscle Biology Group, Meakins–Christie Laboratories, McGill University, Montreal, Quebec, Canada
Search for more papers by this authorJun Luo MD
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Respiratory Muscle Biology Group, Meakins–Christie Laboratories, McGill University, Montreal, Quebec, Canada
Search for more papers by this authorCorresponding Author
Basil J. Petrof MD
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Respiratory Muscle Biology Group, Meakins–Christie Laboratories, McGill University, Montreal, Quebec, Canada
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, CanadaSearch for more papers by this authorLiying Yang MD
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Respiratory Muscle Biology Group, Meakins–Christie Laboratories, McGill University, Montreal, Quebec, Canada
Search for more papers by this authorJun Luo MD
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Respiratory Muscle Biology Group, Meakins–Christie Laboratories, McGill University, Montreal, Quebec, Canada
Search for more papers by this authorCorresponding Author
Basil J. Petrof MD
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada
Respiratory Muscle Biology Group, Meakins–Christie Laboratories, McGill University, Montreal, Quebec, Canada
Respiratory Division, Room L411, Royal Victoria Hospital, 687 Pine Avenue West, Montreal, Quebec H3A 1A1, CanadaSearch for more papers by this authorAbstract
The effects of methylprednisolone therapy on the susceptibility of dystrophin-deficient myofibers to contraction-induced injury were evaluated in the mdx mouse diaphragm model of Duchenne dystrophy. Mdx myofibers were abnormally vulnerable to injury induced by high-stress eccentric contractions. However, methylprednisolone therapy did not significantly alter the degree of contraction-induced injury. These data suggest that beneficial effects of corticosteroid therapy in Duchenne dystrophy are unlikely to be related to a change in the threshold for contraction-induced myofiber damage. © 1998 John Wiley & Sons, Inc. Muscle Nerve 21:394–397, 1998.
References
- 1
Anderson JE,
McIntosh LM,
Poettcker R:
Deflazacort but not prednisone improves both muscle repair and fiber growth in diaphragm and limb muscle in vivo in the mdx dystrophic mouse.
Muscle Nerve
1996;
19:
1576–1585.
10.1002/(SICI)1097-4598(199612)19:12<1576::AID-MUS7>3.0.CO;2-7 CAS PubMed Web of Science® Google Scholar
- 2 Angelini C, Pegoraro E, Turella E, Intino MT, Pini A, Costa C: Deflazacort in Duchenne dystrophy: study of long term effect. Muscle Nerve 1994; 17: 386–391.
- 3 Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, Kaiser KK, Florence JM, Pandya S, Signore L, King W, Robinson J, Head RA, Province MA, Seyfried W, Mandel S: Clinical investigation of Duchenne dystrophy: interesting results in a trial of prednisone. Arch Neurol 1987; 44: 812–817.
- 4 Burrow KL, Coovert DD, Klein CJ, Bulman DE, Kissel JT, Rammohan KW, Burghes AHM, Mendell JR, and the CIDD Study Group: Dystrophin expression and somatic reversion in prednisone-treated and untreated Duchenne dystrophy. Neurology 1991; 41: 661–666.
- 5 DeSilva S, Drachman DB: Prednisone treatment in Duchenne muscular dystrophy. Long term benefit. Arch Neurol 1987; 44: 818–822.
- 6 Fenichel GM, Florence JM, Pestronk A, Mendell JR, Moxley RT, Griggs RC, Brooke MH, Miller JP, Robinson J, King W, Signore L, Pandya S, Schierbecker J, Wilson B: Long-term benefit from prednisone therapy in Duchenne muscular dystrophy. Neurology 1991; 41: 1874–1877.
- 7 Griggs RC, Moxley RT, Mendell JR, Fenichel GM, Brooke MH, Pestronk A, Miller JP, and the Clinical Investigation of Duchenne Dystrophy Group: Prednisone in Duchenne dystrophy. Arch Neurol 1991; 48: 383–388.
- 8 Guerriero V Jr, Florini JR: Dexamethasone effects on myoblast proliferation and differentiation. Endocrinology 1980; 106: 1198–1202.
- 9 Hoffman EP, Brown RHJ, Kunkel LM: Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51: 919–928.
- 10 Hudecki MS, Pollina CM, Granchelli JA, Daly MK, Byres T. Wang JC, Hsiao JC: Strength and endurance in the therapeutic evaluation of prednisolone-treated mdx mice. Res Commun Chem Pathol Pharmacol 1993; 79: 45–60.
- 11 Jones DA, Newham DJ, Round JM, Tolfree SEJ: Experimental human muscle damage: morphological changes in relation to other indices of damage. J Physiol 1986; 375: 435–448.
- 12 Kawai H, Adachi K, Nishida Y, Inui T, Kimura C, Saito S: Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment. J Neurol 1993; 240: 181–186.
- 13 Khan MA: Corticosteroid therapy in Duchenne muscular dystrophy. J Neurol Sci 1993; 120: 8–14.
- 14 Kissel JT, Burrow KL, Rammohan KW, Mendell JR, CIDD Study Group: Mononuclear cell analysis of muscle biopsies in prednisone-treated and untreated Duchenne muscular dystrophy. Neurology 1991; 41: 667–672.
- 15 Kissel JT, Lynn DJ, Rammohan KW, Klein JP, Griggs RC, Moxley RT3d, Cwik VA, Brooke MH, Mendell JR: Mononuclear cell analysis of muscle biopsies in prednisone- and azathioprine-treated Duchenne muscular dystrophy. Neurology 1993; 43: 532–536.
- 16 McCully K, Giger U, Argov Z, Valentine B, Cooper B, Chance B, Bank W: Canine X-linked muscular dystrophy studied with in vivo phosphorus magnetic resonance spectroscopy. Muscle Nerve 1991; 14: 1091–1098.
- 17 McCully KK, Faulkner JA: Characteristics of lengthening contractions associated with injury to skeletal muscle fibers. J Appl Physiol 1986; 61: 293–299.
- 18 McNeil PL, Khakee R: Disruptions of muscle fiber plasma membranes. Role in exercise-induced damage. Am J Pathol 1992; 140: 1097–1109.
- 19 Mendell JR, Moxley RT, Griggs RC, Brooke MH, Fenichel GM, Miller JP, King W, Signore L, Pandya S, Florence J, Schierbecker J, Robinson J, Kaiser K, Mandel S, Arfken C, Gilder B: Randomized double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 1989; 320: 1592–1597.
- 20 Menke A, Jockusch H: Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. Nature 1991; 349: 69–71.
- 21 Mesa LE, Dubrovsky AL, Corderi J, Marco P, Flores D: Steroids in Duchenne muscular dystrophy-deflazacort trial. Neuromusc Disord 1992; 1: 261–266.
- 22 Metzinger L, Passaquin A-C, Warter J-M, Poindron P: a-Methylprednisolone promoted skeletal myogenesis in dystrophin-deficient and control mouse cultures. Neurosci Lett 1993; 155: 171–174.
- 23 Pasquini F, Guerin C, Blake D, Davies K, Karpati G, Holland P: The effect of glucocorticoids on the accumulation of utrophin by cultured normal and dystrophic human skeletal muscle satellite cells. Neuromusc Disord 1995; 5: 105–114.
- 24 Passaquin AC, Metzinger L, Leger JJ, Warter J-M, Poindron P: Prednisone enhances myogenesis and dystrophin-related protein in skeletal muscle cell clusters from mdx mouse. J Neurosci Res 1993; 35: 363–372.
- 25 Pasternak C, Wong S, Elson EL: Mechanical function of dystrophin in muscle cells. J Cell Biol 1995; 128: 355–361.
- 26 Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL: Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc Natl Acad Sci USA 1993; 90: 3710–3714.
- 27 Petrof BJ, Stedman HH, Shrager JB, Eby J, Sweeney HL, Kelly AM: Adaptations in myosin heavy chain expression and contractile function in the dystrophic (MDX) mouse diaphragm. Am J Physiol 1993; 265: C834–C841.
- 28 Sklar RM, Brown RHJ: Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro. J Neurol Sci 1991; 101: 73–81.
- 29 Stauber WT: Eccentric action of muscles: physiology, injury, and adaptation. Exer Sport Sci Rev 1989; 17: 157–185.
- 30 Stedman HH, Sweeney HL, Shrager JB, Maguire HC, Panettieri RA, Petrof B, Narusawa M, Leferovich JM, Sladky JT, Kelly AM: The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 1991; 352: 536–539.
- 31 Stracher A: Proteinase inhibitors and muscle degeneration. Muscle Nerve 1982; 5: 494.
- 32 Weller B, Karpati G, Carpenter S: Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. J Neurol Sci 1990; 100: 9–13.
- 33 Whitaker JN, Bertorini TE, Mendell JR: Immunocytochemical studies of cathepsin D in human skeletal muscle. Ann Neurol 1983; 13: 133–142.
Citing Literature
